MSD provides update on next steps for suspension of TredaptiveT (nicotinic acid/laropiprant)

Source: MSD Area: News MSD has announced that it is taking steps to suspend the availability of TredaptiveT (nicotinic acid/laropiprant, MSD) modified-release tablets worldwide. This action follows company the release of preliminary data from the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study, and in consultation with regulatory authorities.   HPS2-THRIVE did not achieve its primary endpoint of reduction of major vascular events, and there was a statistically significant increase in the incidence of some types of non-fatal serious adverse events in the group that received Tredaptive compared to statin therapy. The decision to suspend availability of the medicine is aligned with the recommendation of the European Medicine Agency's Pharmacovigilance Risk Assessment Committee (PRAC) based on the trial's results. In countries where the medicine is currently available, MSD has begun informing regulatory agencies of the company's decision. MSD ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news